RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNXT RenovoRx Inc

Closed 11-22 16:00:00 EST

1.29

+0.08

+6.60%

盘后1.29

+0.000.00%

19:37 EST

High1.58	Low1.18	Vol263.03K
Open1.30	D1 Closing1.21	Amplitude32.72%
Mkt Cap30.94M	Tradable Cap30.35M	Total Shares23.99M
T/O359.88K	T/O Rate1.12%	Tradable Shares23.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"RNXT","market":"US","secType":"STK","nameCN":"RenovoRx Inc","latestPrice":1.29,"timestamp":1732309200000,"preClose":1.2101,"halted":0,"volume":263026,"hourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.29,"latestTime":"19:37 EST","volume":1643,"amount":2107.27,"timestamp":1732322258886},"delay":0,"floatShares":23530009,"shares":23986709,"eps":-0.492604,"marketStatus":"Closed","change":0.0799,"latestTime":"11-22 16:00:00 EST","open":1.3,"high":1.58,"low":1.1841,"amount":359884.19348819996,"amplitude":0.327163,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.492604,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":5,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":1.2101,"preHourTrading":{"tag":"盘前","latestPrice":1.3,"preClose":1.23,"latestTime":"09:29 EST","volume":1600,"amount":2050.32,"timestamp":1732285799091},"postHourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.29,"latestTime":"19:37 EST","volume":1643,"amount":2107.27,"timestamp":1732322258886},"volumeRatio":2.801135},"requestUrl":"/m/hq/s/RNXT/tweets","defaultTab":"tweets","newsList":[{"id":"2484424117","title":"RenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484424117","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484424117?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:40","pubTimestamp":1732113613,"startTime":"0","endTime":"0","summary":"RenovoRx  said Wednesday that New York-based Northwell Health Cancer Institute started enrolling patients with advanced pancreatic cancer in an ongoing phase III trial that will evaluate the Trans-Arterial Micro-Perfusion therapy platform.The study will use RenovoRx's TAMP therapy platform to evaluate its first drug-device combination product candidate, which is an intra-arterial infusion of gemcitabine via the RenovoCath delivery system. The study will compare treatment with TAMP versus the current standard-of-care chemotherapy, according to the company.Shares of RenovoRx were up more than 4% in early morning trade.Price: 1.16, Change: +0.05, Percent Change: +4.32","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["III","BK4139","BK4134","BK4539","RNXT"],"gpt_icon":0},{"id":"2484811156","title":"RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484811156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484811156?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:50","pubTimestamp":1732110652,"startTime":"0","endTime":"0","summary":"RenovoRx (RNXT) announced that the Northwell Health Cancer Institute, NHCI, in New Hyde Park, NY is enrolling patients with locally advanced pancre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-announces-nhci-is-enrolling-patients-for-phase-iii-tiger-pac-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-announces-nhci-is-enrolling-patients-for-phase-iii-tiger-pac-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4134","III","RNXT"],"gpt_icon":0},{"id":"2484197341","title":"Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase Iii Tiger-Pac Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484197341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484197341?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:45","pubTimestamp":1732110300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUAC2BTYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0},{"id":"2484826111","title":"Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484826111","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484826111?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:45","pubTimestamp":1732110300,"startTime":"0","endTime":"0","summary":"The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025. Phase III Clinical Trial is Evaluating the TAMP  Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer. The TIGeR-PaC study is using RenovoRx’s TAMP  therapy platform, to evaluate the Company’s first drug-device combination product candidate . TAMP utilizes pressure-mediated delivery of gemcitabine to the target tumor. The study is comparing treatment with TAMP in LAPC to the current standard-of-care .About Locally Advanced Pancreatic Cancer According to the American Cancer Society’s Cancer Facts & Figures 2024 and PanCAN, respectively, pancreatic cancer has a 5-year all stages combined relative survival rate of 13%  and is on track to be the second leading cause of cancer-related deaths before 2030. LAPC is diagnosed when the disease has not spread far beyond the pancreas, however, has advan","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GCcNodqMNCZfYujKuJgZQA--~B/aD02MDt3PTM4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4d894f618cb1c03007130653928a8acf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GCcNodqMNCZfYujKuJgZQA--~B/aD02MDt3PTM4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4d894f618cb1c03007130653928a8acf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/northwell-health-cancer-institute-launches-134500021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4134","III","RNXT","BK4539","BK4139"],"gpt_icon":0},{"id":"2483530847","title":"Positive Outlook for RenovoRx: Promising TIGeR-PaC Phase 3 Trial Results and Innovative Drug Delivery Platform Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483530847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483530847?lang=en_us&edition=fundamental","pubTime":"2024-11-15 23:15","pubTimestamp":1731683736,"startTime":"0","endTime":"0","summary":"Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on RenovoRx (RNXT – Research Report). The associated price target is $4.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-renovorx-promising-tiger-pac-phase-3-trial-results-and-innovative-drug-delivery-platform-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-renovorx-promising-tiger-pac-phase-3-trial-results-and-innovative-drug-delivery-platform-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"gpt_icon":0},{"id":"2483700870","title":"RenovoRx Q3 EPS $(0.10), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483700870","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483700870?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:23","pubTimestamp":1731590618,"startTime":"0","endTime":"0","summary":"RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 23.08 percent increase over losses of $(0.13) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41971098/renovorx-q3-eps-0-10-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"RenovoRx Q3 EPS $(0.10), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2478976288","title":"We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2478976288","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478976288?lang=en_us&edition=fundamental","pubTime":"2024-10-26 21:43","pubTimestamp":1729950190,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rnxt/renovorx/news/we-think-renovorx-nasdaqrnxt-needs-to-drive-business-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4112","PSQ","BK4539","BK4588","SQQQ","IE00B64PRP62.GBP","MNQmain","QID","LU2210150020.SGD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","NQmain",".IXIC","BK4139","IE00B3QW5Z07.USD","BK4585","RNXT","TQQQ","QLD"],"gpt_icon":1},{"id":"2470625911","title":"RenovoRx Increases Production of FDA-Cleared Renovocath® Delivery System in Response to Strong Demand From Oncology and Interventional Radiology Physicians","url":"https://stock-news.laohu8.com/highlight/detail?id=2470625911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470625911?lang=en_us&edition=fundamental","pubTime":"2024-09-25 20:30","pubTimestamp":1727267400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240925:nTUA86BZ0L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","RNXT"],"gpt_icon":0},{"id":"2470259437","title":"RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians","url":"https://stock-news.laohu8.com/highlight/detail?id=2470259437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470259437?lang=en_us&edition=fundamental","pubTime":"2024-09-25 20:30","pubTimestamp":1727267400,"startTime":"0","endTime":"0","summary":"Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/25/2952952/0/en/RenovoRx-Increases-Production-of-FDA-Cleared-RenovoCath-Delivery-System-in-Response-to-Strong-Demand-from-Oncology-and-Interventional-Radiology-Physicians.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0},{"id":"2468576955","title":"RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting Tamp™ for Targeted Treatment of Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2468576955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468576955?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:30","pubTimestamp":1726749000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nTUA9PYJXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0},{"id":"2468046576","title":"RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2468046576","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468046576?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:30","pubTimestamp":1726749000,"startTime":"0","endTime":"0","summary":"Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-monthsLOS ALTOS, Calif., Sept.  19, 2024  (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/19/2948987/0/en/RenovoRx-Announces-Presentation-at-Symposium-on-Clinical-Interventional-Oncology-Highlighting-TAMP-for-Targeted-Treatment-of-Locally-Advanced-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4157","IE0031619046.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","BK4539","RNXT","IE00B66KJ199.SGD","AEIS","BK4139"],"gpt_icon":0},{"id":"2466242899","title":"U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2466242899","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466242899?lang=en_us&edition=fundamental","pubTime":"2024-09-12 15:46","pubTimestamp":1726127185,"startTime":"0","endTime":"0","summary":"Sept 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cintas Corp, Sprouts Farmers market and Voya Financial, on Thurs","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4108","IE00BGHQF524.EUR","BK4106","PT","IE00BKPKM429.USD","VNOM","IE00B3QW5Z07.USD","RNXT","PAYX","LU0738911758.USD","IE00BZ1G4Q59.USD","IE0002270589.USD","IE00BGHQF748.EUR","IE00B2Q91V27.USD","IE00BSNM7G36.USD","LU0661504455.SGD","GILD","BK4113","LU0058720904.USD","LU1585245621.USD","BK4223","BK4532","ALLY","LU0949170772.SGD","LKQ","SFM","VOYA","BK4166","ALHC","BK4162","BK4539","IE00B64PRP62.GBP","ARI","LU0061475181.USD","LU0289739699.SGD","LNC","IE00B3CCJ963.GBP","LU0234570918.USD","LU2468319806.SGD","BK4154","NBTB","LU2092937221.SGD","VNO","FANG","CTAS","BK4184","LU0320765992.SGD","SEAT","NDAQ"],"gpt_icon":0},{"id":"2466243968","title":"RenovoRx Inc : Ascendiant Capital Markets Raises Target Price to $8.25 From $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2466243968","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466243968?lang=en_us&edition=fundamental","pubTime":"2024-09-12 14:15","pubTimestamp":1726121715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nFWN3KU02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0},{"id":"2462316414","title":"RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York","url":"https://stock-news.laohu8.com/highlight/detail?id=2462316414","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462316414?lang=en_us&edition=fundamental","pubTime":"2024-08-27 20:30","pubTimestamp":1724761800,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Aug.  27, 2024  (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology thera","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/27/2936225/0/en/RenovoRx-CEO-Shaun-Bagai-to-Present-at-H-C-Wainwright-s-26th-Annual-Global-Investment-Conference-on-September-9-2024-in-New-York.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0},{"id":"2459470682","title":"Buy Rating Backed by RenovoRx’s Clinical Advancements and Sustained Financial Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2459470682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459470682?lang=en_us&edition=fundamental","pubTime":"2024-08-16 00:35","pubTimestamp":1723739732,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy maintained a Buy rating on RenovoRx (RNXT – Research Report) yesterday and set a price target of $4.00. Jason Mc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-backed-by-renovorxs-clinical-advancements-and-sustained-financial-health?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-backed-by-renovorxs-clinical-advancements-and-sustained-financial-health?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"gpt_icon":0},{"id":"2459475665","title":"RenovoRx Inc reports results for the quarter ended in June - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2459475665","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459475665?lang=en_us&edition=fundamental","pubTime":"2024-08-15 22:26","pubTimestamp":1723732008,"startTime":"0","endTime":"0","summary":"* RenovoRx Inc    reported a quarterly adjusted loss of 10 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -31 cents.  The mean ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"RenovoRx Inc reports results for the quarter ended in June - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2459734401","title":"RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase Iii Tiger-Pac Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2459734401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459734401?lang=en_us&edition=fundamental","pubTime":"2024-08-14 20:30","pubTimestamp":1723638601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240814:nTUAC9QYDG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","RNXT"],"gpt_icon":0},{"id":"2459173238","title":"RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2459173238","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459173238?lang=en_us&edition=fundamental","pubTime":"2024-08-14 20:30","pubTimestamp":1723638600,"startTime":"0","endTime":"0","summary":"Phase III clinical trial is evaluating RenovoGem for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/14/2930056/0/en/RenovoRx-Announces-First-Patient-Enrolled-at-University-of-Nebraska-Medical-Center-for-the-Ongoing-Pivotal-Phase-III-TIGeR-PaC-Clinical-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","III","BK4134","RNXT"],"gpt_icon":0},{"id":"2455138749","title":"RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®","url":"https://stock-news.laohu8.com/highlight/detail?id=2455138749","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455138749?lang=en_us&edition=fundamental","pubTime":"2024-07-31 20:30","pubTimestamp":1722429000,"startTime":"0","endTime":"0","summary":"Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer (LAPC) observed an Overall Survival (OS) of 27-months Targeted chemotherapy de","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/07/31/2921870/0/en/RenovoRx-Announces-Publication-of-Positive-Early-Stage-Clinical-Data-in-International-Peer-Reviewed-Journal-The-Oncologist.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","OS","RNXT","BK4097","SSI"],"gpt_icon":0},{"id":"2449721387","title":"RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®","url":"https://stock-news.laohu8.com/highlight/detail?id=2449721387","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449721387?lang=en_us&edition=fundamental","pubTime":"2024-07-08 20:30","pubTimestamp":1720441800,"startTime":"0","endTime":"0","summary":"Publication of data relating to RenovoRx’s targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journalLOS AL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/07/08/2909624/0/en/RenovoRx-Announces-Acceptance-for-Publication-in-the-International-Peer-Reviewed-Journal-The-Oncologist.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovorx.com","stockEarnings":[{"period":"1week","weight":0.1102},{"period":"1month","weight":0.2101},{"period":"3month","weight":0.1984},{"period":"6month","weight":-0.0396},{"period":"1year","weight":0.8646},{"period":"ytd","weight":-0.4716}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.17996},{"month":2,"riseRate":1,"avgChangeRate":0.308925},{"month":3,"riseRate":0,"avgChangeRate":-0.199815},{"month":4,"riseRate":0,"avgChangeRate":-0.209638},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.09114},{"month":6,"riseRate":0.666667,"avgChangeRate":0.066465},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.026625},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.08395},{"month":9,"riseRate":0.25,"avgChangeRate":-0.143321},{"month":10,"riseRate":0,"avgChangeRate":-0.119349},{"month":11,"riseRate":0.75,"avgChangeRate":0.063752},{"month":12,"riseRate":0.666667,"avgChangeRate":0.82229}],"exchange":"NASDAQ","name":"RenovoRx Inc","nameEN":"RenovoRx Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RenovoRx Inc,RNXT,RenovoRx Inc股票,RenovoRx Inc股票老虎,RenovoRx Inc股票老虎国际,RenovoRx Inc行情,RenovoRx Inc股票行情,RenovoRx Inc股价,RenovoRx Inc股市,RenovoRx Inc股票价格,RenovoRx Inc股票交易,RenovoRx Inc股票购买,RenovoRx Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction